CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Hold” by Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been assigned a consensus recommendation of “Hold” from the eighteen analysts that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $75.71.

A number of equities research analysts have recently weighed in on CRSP shares. Wells Fargo & Company dropped their price objective on CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating for the company in a research note on Thursday, May 9th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Robert W. Baird boosted their target price on CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a report on Thursday, May 9th. Piper Sandler reissued an “overweight” rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a report on Monday, June 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $88.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, June 27th.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $53.10 on Friday. CRISPR Therapeutics has a 1-year low of $37.55 and a 1-year high of $91.10. The company has a market cap of $4.51 billion, a PE ratio of -19.52 and a beta of 1.70. The stock’s 50 day simple moving average is $56.57 and its 200-day simple moving average is $64.20.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $25.53 million. During the same quarter in the prior year, the company earned ($0.67) EPS. The firm’s revenue for the quarter was down 99.5% on a year-over-year basis. On average, equities research analysts anticipate that CRISPR Therapeutics will post -5.51 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Julianne Bruno sold 3,366 shares of the stock in a transaction on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The disclosure for this sale can be found here. 4.10% of the stock is owned by insiders.

Institutional Trading of CRISPR Therapeutics

Several large investors have recently modified their holdings of CRSP. Invesco Ltd. lifted its holdings in CRISPR Therapeutics by 1.5% in the third quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock worth $6,179,000 after acquiring an additional 2,061 shares during the last quarter. Seven Eight Capital LP bought a new stake in CRISPR Therapeutics during the third quarter worth approximately $734,000. WealthPlan Investment Management LLC raised its holdings in CRISPR Therapeutics by 16,063.8% during the third quarter. WealthPlan Investment Management LLC now owns 9,375 shares of the company’s stock worth $426,000 after purchasing an additional 9,317 shares in the last quarter. Integrated Advisors Network LLC acquired a new position in CRISPR Therapeutics in the third quarter worth approximately $327,000. Finally, B. Riley Wealth Advisors Inc. grew its position in CRISPR Therapeutics by 104.7% in the third quarter. B. Riley Wealth Advisors Inc. now owns 16,810 shares of the company’s stock worth $763,000 after buying an additional 8,597 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.